BioTools Innovator VANGUARD awards CellChorus contract to support AI-enabled pathogen-immune profiling
Funding from BioTools Innovator-BARDA partnership to accelerate drug development to combat infectious diseases caused by fungal pathogens
HOUSTON, Texas — August 25, 2025 — CellChorus Inc., the leader in applying artificial intelligence to visually evaluate how cells perform and interact over time, announced today that BioTools Innovator (BTI) VANGUARD has awarded CellChorus® a $200,000 non-dilutive funding contract to support development of AI-enabled pathogen-immune profiling using TIMING™ single-cell assays. The principal investigators on the project are Rebecca Berdeaux, PhD, and Hannah Wilson, PhD.
